Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Editorial opinion

June 9th 2016

HbA1c targets and hypoglycaemia  

Mention the term hypoglycaemia (hypo) to many health care professionals and what comes to mind? Perhaps something to record on the relevant template or an inconvenience that requires minimal medication adjustment. However, this can be a gross underestimate given that, from the patient point of view, hypos are often feared requiring them to make significant changes to daily activity in order to avoid them. This is not without significant reason – hypos can result in significant problems such as falls, accidents or even death (the dead in bed syndrome). Hypo frequency and severity are influenced by a variety of conditions including diet and exercise but as the plethora of hypoglycaemic agents increase in number, treatment choice is clearly a major issue in determining their frequency.

This week’s publication of JAMA reinforces this by providing evidence that than 20% of patients with type 2 diabetes received intensive treatment that may be unnecessary. Among patients with high clinical complexity, intensive treatment nearly doubles the risk of severe hypoglycaemia (defined as hypoglycaemia requiring third party assistance).

One of the benefits of the recent NICE guidance for Type 2 diabetes is the frequent mention of individualising treatment options, specifically taking hypoglycaemia into account. This is reflected in differing targets for HbA1c – 6.5% in most patients but 7.0% if the patient is taking a drug associated with hypoglycaemia such as a sulphonylurea. However, despite this guidance, many patients targets are set inappropriately low, perhaps generated by the desire to reach the relevant QoF target instead of focusing care to the patient. For example, it may be preferable to set a target A1c of <6.5% for a young person with retinopathy but between 8.5-9.5% for an elderly patient living alone where hypoglycaemia may have major consequences. The frequent conflict between individual patient care and funding related targets seems set to continue.

Dr. Mark Freeman

Categories: News

Categories:

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesAstraZenecaNovo NordiskNapp Diabetes

Silver Sponsors

AmgenWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Emergency Medicine
  • Handbook of Obstetric Medicine
  • Ferri’s Clinical Advisor 2021
  • Oxford Case Histories in Infectious Diseases and Microbiology

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2021 Glycosmedia Partnership